Boomfish Wealth Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Boomfish Wealth Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.29M	Sell	4,383 -1,151	-21%	-$589K	0.99%	39
2026 Q2	$2.75M	Sell	5,534 -929	-14%	-$412K	1.25%	31
2026 Q1	$2.89M	Buy	6,463 +53	+0.8%	+$24.7K	1.54%	23
2025 Q4	$2.91M	Sell	6,410 -237	-4%	-$102K	1.55%	25
2025 Q3	$2.6M	Buy	6,647 +1,404	+27%	+$587K	1.4%	32
2025 Q2	$2.33M	Buy	5,243 +192	+4%	+$88.5K	1.35%	34
2025 Q1	$2.45M	Sell	5,051 -41	-0.8%	-$19.1K	1.59%	21
2024 Q4	$2.05M	Buy	5,092 +268	+6%	+$124K	1.24%	36
2024 Q3	$2.24M	Sell	4,824 -151	-3%	-$72.5K	1.38%	35
2024 Q2	$2.33M	Sell	4,975 -107	-2%	-$46.4K	1.51%	27
2024 Q1	$2.12M	Sell	5,082 -350	-6%	-$148K	1.43%	36
2023 Q4	$2.21M	Buy	+5,432	New	+$2.01M	1.6%	25

Other funds holding VRTX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Boomfish Wealth Group's VRTX Position: Q3 2026 in Review

Boomfish Wealth Group reduced its Vertex Pharmaceuticals (VRTX) stake by 21% in Q3 2026, selling an estimated $589K and leaving 4,383 shares worth $2.29M. The position accounts for 0.99% of the portfolio, ranked #39.

Boomfish Wealth Group first reported a position in VRTX in Q4 2023 and has held it in 12 quarters since. The position peaked at $2.91M in Q4 2025. 992 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Boomfish Wealth Group held 4,383 shares of Vertex Pharmaceuticals worth $2.29M as of Q3 2026.
Boomfish Wealth Group sold 1,151 Vertex Pharmaceuticals shares in Q3 2026, an estimated $589K.
Vertex Pharmaceuticals made up 0.99% of Boomfish Wealth Group's portfolio in Q3 2026, its #39 holding.
Boomfish Wealth Group first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
Boomfish Wealth Group's Vertex Pharmaceuticals position peaked at $2.91M in Q4 2025.
992 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Boomfish Wealth Group's 13F filing for Q3 2026, filed 22 Oct 2026.